《美股業績》雅培(ABT.US)季績勝預期 稱新減肥藥助葡萄糖檢測銷售
美國雅培實驗室(ABT.US)公布第三季業績。季度利潤按年升0.1%至14.36億美元,每股季度純利82美仙,經調整後為1.14美元,高於市場預期的1.1美元。季度淨銷售按年跌2.6%至101.43億美元。
其中醫療設備銷售按年升16.6%至42.49億美元,高於市場預期的41.6億美元。檢測設備及工具套銷售跌近三分一至24.5億美元,受新冠相關檢測需求急跌影響。連續葡萄糖監測儀Freestyle Libre帶來約14億美元銷售,高於第二季的13億美元,佔整體收入近14%。公司稱,該監測儀銷售隨同業新減肥藥應用增加而上升。
公司預期全年每股盈利介乎4.42至4.46美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.